Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study
暂无分享,去创建一个
H. Wiendl | J. Howard | F. O'Brien | K. Utsugisawa | S. Jacob | H. Murai | R. Nowak | K. Fujita | S. Jacob
[1] T. Levine. Safety of an Abbreviated Transition Period When Switching From Intravenous Immunoglobulin to Eculizumab in Patients with Treatment-Refractory Myasthenia Gravis: A Case Series , 2019, The American journal of case reports.
[2] A. Exuzides,et al. Healthcare resource utilization by patients with treatment-refractory myasthenia gravis in England , 2019, Journal of medical economics.
[3] M. Benatar,et al. Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis , 2019, Muscle & nerve.
[4] N. Engel-Nitz,et al. Burden of illness in patients with treatment refractory myasthenia gravis , 2018, Muscle & nerve.
[5] G. L. Masson,et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. , 2017, The Lancet. Neurology.
[6] M. Benatar,et al. International consensus guidance for management of myasthenia gravis , 2016, Neurology.
[7] J. Goldstein,et al. Clinical Characteristics of Refractory Myasthenia Gravis Patients , 2013, The Yale journal of biology and medicine.
[8] Richard J. Jones,et al. Rebooting the Immune System with High‐Dose Cyclophosphamide for Treatment of Refractory Myasthenia Gravis , 2008, Annals of the New York Academy of Sciences.
[9] J. Suarez,et al. Myasthenia Gravis Crisis , 2008, Southern medical journal.
[10] M. Dalakas,et al. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. , 1994, The Journal of clinical investigation.